NCT03157128 2026-04-16LIBRETTO-001Eli Lilly and CompanyPhase 1/2 Active not recruiting857 enrolled 24 charts 6 FDA
NCT03155620 2026-04-14Targeted Therapy Directed by Genetic Testing in Treating Pediatric Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphomas, or Histiocytic Disorders (The Pediatric MATCH Screening Trial)National Cancer Institute (NCI)Phase 2 Active not recruiting1,377 enrolled 10 charts